<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00090753</url>
  </required_header>
  <id_info>
    <org_study_id>BH18387</org_study_id>
    <nct_id>NCT00090753</nct_id>
  </id_info>
  <brief_title>A Study of Intravenous or Subcutaneous Methoxy Polyethylene Glycol-Epoetin Beta (RO0503821, Mircera) in Chronic Kidney Disease Patients With Renal Anemia</brief_title>
  <official_title>An Open-label, Multi-center Study to Document the Efficacy, Safety, and Tolerability of Long-term Administration of RO0503821 in Patients With Chronic Renal Anemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This study assessed the long-term efficacy, safety, and tolerability of intravenous (iv) or
      subcutaneous (sc) methoxy polyethylene glycol-epoetin beta in chronic kidney disease patients
      with renal anemia. Eligible patients were those who were receiving stable maintenance therapy
      with methoxy polyethylene glycol-epoetin beta or erythropoiesis stimulating agents (ESAs) in
      Phase II or III clinical studies. They continued to receive methoxy polyethylene
      glycol-epoetin beta or comparator ESAs at the same weekly dose and by the same route of
      administration (sc or iv) as in the qualifying studies.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2004</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Hemoglobin Concentration to the Last Month of Study Participation</measure>
    <time_frame>Baseline to the end of the study (Up to 49 Months)</time_frame>
    <description>Blood samples were collected at each study visit, that is, every 4 weeks for the first 12 weeks, every 12 weeks until week 105 of the first study period, every 3 months thereafter, and at the end of study or the last visit if the patient discontinued the study prematurely.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Who Had at Least 1 Adverse Event</measure>
    <time_frame>From first dose of study drug to date of last contact or 30 days after last drug dose (Up to 49 months)</time_frame>
    <description>See the adverse events section of the results for more information.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1228</enrollment>
  <condition>Anemia</condition>
  <arm_group>
    <arm_group_label>Methoxy Polyethylene Glycol-Epoetin Beta</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients received the same weekly dose of methoxy polyethylene glycol-epoetin beta via the same route of administration (iv or sc) as they received in the Phase II or Phase III study that qualified the patient for participation in this study. Methoxy polyethylene glycol-epoetin beta was administered every 2 or every 4 weeks in the initial 104-week treatment period. Patients on a 4-week dosing interval were switched to once-monthly administration in the 24-month extension phase. The dose of methoxy polyethylene glycol-epoetin beta was adjusted to maintain the patient's hemoglobin (Hb) within a target range of 11 to 13 g/dL.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator ESA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients received the same comparator ESA [epoetin alfa, epoetin beta, or darbepoetin alfa] at the same weekly dose and dosing interval via the same route of administration (iv or sc) as they received in the Phase III study that qualified the patient for participation in this study. The dose of the comparator drug was adjusted to maintain the patient's Hb within a target range of 11 to 13 g/dL. Of the 480 patients in the comparator drug group, 170 received darbepoetin alfa, 134 received epoetin alfa, and 176 received epoetin beta.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methoxy Polyethylene Glycol-Epoetin Beta</intervention_name>
    <description>Methoxy polyethylene glycol-epoetin beta was provided as a sterile single-use injectable solution in 2-mL glass vials containing 1 mL solution or in single-use sterile pre-filled syringes (PFSs) containing 0.3 mL or 0.6 mL injectable solution. The injectable solution was available in vials with the following strengths: 50, 100, 200, 400, and 1000 μg/mL. The injectable solution was available in PFSs with the following strengths: 30, 40, 50, 60, 75, 100, 120, 150, 200, and 250 μg/0.3 mL; and 360 and 400 μg/0.6 mL.</description>
    <arm_group_label>Methoxy Polyethylene Glycol-Epoetin Beta</arm_group_label>
    <other_name>RO0503821</other_name>
    <other_name>Mircera</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epoetin alfa</intervention_name>
    <description>Epoetin alfa was provided with commercial packaging in English with country-specific labels (10,000 IU, 20,000 IU).</description>
    <arm_group_label>Comparator ESA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epoetin beta</intervention_name>
    <description>Epoetin beta was provided with commercial packaging in English with country-specific labels (50,000 IU, 100,000 IU).</description>
    <arm_group_label>Comparator ESA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Darbepoetin alfa</intervention_name>
    <description>Darbepoetin alfa was provided with commercial packaging in English with country-specific labels (vials and PFSs in various strengths).</description>
    <arm_group_label>Comparator ESA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent

          -  Adult patients (≥ 18 years old) with chronic renal anemia

          -  Maintenance erythropoietic therapy with methoxy polyethylene glycol-epoetin beta or a
             protocol-specified reference medication (epoetin alfa formulated with human albumin,
             epoetin beta or darbepoetin alfa) in one of the following studies:
             BA16528[NCT00048048], BA16285[NCT00048035], BA16286[NCT00364832],
             BA16736[NCT00077597], BA16738[NCT00081471], BA16739[NCT00077610],
             BA16740[NCT00077623], BA17283[NCT00077766] and BA17284[NCT00081484]

          -  Hemoglobin (Hb) concentration between 10.5 and 13.0 g/dL

          -  Adequate iron status defined as serum ferritin ≥ 100 ng/mL or Transferrin Saturation
             (TSAT)≥ 20% or percentage of hypochromic red blood cells (RBCs) &lt; 10%

        Exclusion Criteria:

          -  Poorly controlled hypertension

          -  History of epileptic seizure

          -  Pure red cell aplasia

          -  Chronic congestive heart failure [New York Heart Association (NYHA) IV]

          -  High likelihood of early withdrawal or interruption of the study

          -  Active malignant disease (except non-melanoma skin cancer)

          -  Life expectancy less than 12 months

          -  Pregnancy or breast-feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montgomery</city>
        <state>Alabama</state>
        <zip>36106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hot Springs</city>
        <state>Arkansas</state>
        <zip>71901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Covina</city>
        <state>California</state>
        <zip>91723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Encino</city>
        <state>California</state>
        <zip>91356</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Alamitos</city>
        <state>California</state>
        <zip>90720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Monterey Park</city>
        <state>California</state>
        <zip>91754</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mountain View</city>
        <state>California</state>
        <zip>94040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816-5119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lakewood</city>
        <state>Colorado</state>
        <zip>80260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stamford</city>
        <state>Connecticut</state>
        <zip>06902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34471</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>South Holland</city>
        <state>Illinois</state>
        <zip>60473</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202-1718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70884</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202-2689</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brooklyn Center</city>
        <state>Minnesota</state>
        <zip>55430</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbus</city>
        <state>Mississippi</state>
        <zip>39705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <zip>38801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paterson</city>
        <state>New Jersey</state>
        <zip>07503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Flushing</city>
        <state>New York</state>
        <zip>11355</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orchard Park</city>
        <state>New York</state>
        <zip>14127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7155</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mount Airy</city>
        <state>North Carolina</state>
        <zip>27030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267-0585</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oregon City</city>
        <state>Oregon</state>
        <zip>97045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97201-2940</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Erie</city>
        <state>Pennsylvania</state>
        <zip>16502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lewistown</city>
        <state>Pennsylvania</state>
        <zip>17044</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orangeburg</city>
        <state>South Carolina</state>
        <zip>29118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78758</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77099</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507-1901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salem</city>
        <state>Virginia</state>
        <zip>24153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clayton</city>
        <zip>3186</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gosford</city>
        <zip>2250</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Liverpool</city>
        <zip>1871</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Parkville</city>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Perth</city>
        <zip>6847</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sydney</city>
        <zip>NSW 2148</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Woolloongabba</city>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aalst</city>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hasselt</city>
        <zip>3500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Liberec</city>
        <zip>460 63</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ostrava</city>
        <zip>708 52</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plzen</city>
        <zip>304 60</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aalborg</city>
        <zip>9100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roskilde</city>
        <zip>4000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>HUS</city>
        <zip>00029</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampere</city>
        <zip>33521</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bayonne</city>
        <zip>64115</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bois Guillaume</city>
        <zip>76233</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boulogne</city>
        <zip>62321</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cabestany</city>
        <zip>66330</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chambery</city>
        <zip>73001</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Colmar</city>
        <zip>68024</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hyeres</city>
        <zip>83400</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Tronche</city>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lyon</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nimes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <zip>75908</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Perpignan</city>
        <zip>66046</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Ouen</city>
        <zip>93400</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint-germain-en-laye</city>
        <zip>78100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salouël</city>
        <zip>80480</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tarbes</city>
        <zip>65013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Thionville</city>
        <zip>57126</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bad Hersfeld</city>
        <zip>36251</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>12045</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dortmund</city>
        <zip>44263</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>München</city>
        <zip>80804</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nürnberg</city>
        <zip>90431</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stuttgart</city>
        <zip>70191</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Villingen-schwenningen</city>
        <zip>78054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wiesbaden</city>
        <zip>65191</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wiesloch</city>
        <zip>69168</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wuppertal</city>
        <zip>42103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Alexandroupolis</city>
        <zip>68100</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ioannina</city>
        <zip>45500</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Larissa</city>
        <zip>41110</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Piraeus</city>
        <zip>18536</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Thessaloniki</city>
        <zip>54629</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <zip>1076</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <zip>1134</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miskolc</city>
        <zip>3526</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pecs</city>
        <zip>7624</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bergamo</city>
        <zip>24128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cagliari</city>
        <zip>91034</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cremona</city>
        <zip>26100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cuneo</city>
        <zip>12100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lecco</city>
        <zip>23900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Livorno</city>
        <zip>57100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lodi</city>
        <zip>26900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Messina</city>
        <zip>98158</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mestre</city>
        <zip>30174</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Modena</city>
        <zip>41100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Prato</city>
        <zip>50047</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Reggio Calabria</city>
        <zip>89100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>S Fermo Della Battaglia</city>
        <zip>22020</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Venezia</city>
        <zip>30122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cuernavaca</city>
        <zip>62448</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mexico City</city>
        <zip>14000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Heerlen</city>
        <zip>6419 PC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Trondheim</city>
        <zip>7006</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Panama City</city>
        <country>Panama</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gdansk</city>
        <zip>80-211</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gdynia</city>
        <zip>81-519</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kielce</city>
        <zip>25-736</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krakow</city>
        <zip>31-501</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lodz</city>
        <zip>90-153</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Poznan</city>
        <zip>60-355</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rzeszow</city>
        <zip>35-055</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Szczecin</city>
        <zip>70-111</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warszawa</city>
        <zip>02-006</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wolomin</city>
        <zip>05-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wroclaw</city>
        <zip>50-417</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Setubal</city>
        <zip>2910-446</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ponce</city>
        <zip>00732</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <zip>123182</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <zip>125101</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <zip>129110</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St Petersburg</city>
        <zip>195067</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St Petersburg</city>
        <zip>197089</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cape Town</city>
        <zip>7925</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durban</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Soweto</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Alcorcon</city>
        <zip>28922</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Alicante</city>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Almería</city>
        <zip>04009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Badalona</city>
        <zip>08915</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bilbao</city>
        <zip>48013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Córdoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hospitalet de Llobregat</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Coruna</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lerida</city>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28805</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oviedo</city>
        <zip>33006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Palma de Mallorca</city>
        <zip>07014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Palma de Mallorca</city>
        <zip>07198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salamanca</city>
        <zip>37008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santander</city>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santiago de Compostela</city>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Huddinge</city>
        <zip>14186</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Karlstad</city>
        <zip>65185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stockholm</city>
        <zip>18288</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Umea</city>
        <zip>90185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aarau</city>
        <zip>5001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lausanne</city>
        <zip>1003</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taichung</city>
        <zip>407</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chiang Mai</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chonburi</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Phitsanulok</city>
        <zip>65000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Belfast</city>
        <zip>BT9 7LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cambridge</city>
        <zip>CB2 2QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Carshalton</city>
        <zip>SM5 1AA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dundee</city>
        <zip>DD1 9SY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Exeter</city>
        <zip>EX2 5DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Glasgow</city>
        <zip>G4 OSF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leicester</city>
        <zip>LE5 4PW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <zip>E1 1BB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <zip>SE22 8PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <zip>SW17 0RE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salford</city>
        <zip>M6 8HD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Swansea</city>
        <zip>SA6 6NL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Panama</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Puerto Rico</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Brazil</country>
    <country>Canada</country>
  </removed_countries>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 3, 2004</study_first_submitted>
  <study_first_submitted_qc>September 3, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 6, 2004</study_first_posted>
  <results_first_submitted>December 1, 2011</results_first_submitted>
  <results_first_submitted_qc>December 1, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 5, 2012</results_first_posted>
  <last_update_submitted>February 10, 2012</last_update_submitted>
  <last_update_submitted_qc>February 10, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 14, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
    <mesh_term>Darbepoetin alfa</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled in one of the following Phase II or Phase III studies: BA16528[NCT00048048], BA16285[NCT00048035], BA16286[NCT00364832], BA16736[NCT00077597], BA16738[NCT00081471], BA16739[NCT00077610], BA16740[NCT00077623], BA17283[NCT00077766] or BA17284[NCT00081484]</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Methoxy Polyethylene Glycol-Epoetin Beta</title>
          <description>Patients received the same weekly dose of methoxy polyethylene glycol-epoetin beta (Mircera) via the same route of administration (iv or sc) as they received in the Phase II or Phase III study that qualified the patient for participation in this study. Methoxy polyethylene glycol-epoetin beta was administered every 2 or every 4 weeks in the initial 104-week treatment period. Patients on a 4-week dosing interval were switched to once-monthly administration in the 24-month extension phase. The dose of methoxy polyethylene glycol-epoetin beta was adjusted to maintain the patient's hemoglobin (Hb) within a target range of 11 to 13 g/dL.</description>
        </group>
        <group group_id="P2">
          <title>Comparator ESA</title>
          <description>Patients received the same comparator erythropoiesis stimulating agent (ESA) [epoetin alfa, epoetin beta, or darbepoetin alfa] at the same weekly dose and dosing interval via the same route of administration (iv or sc) as they received in the Phase III study that qualified the patient for participation in this study. The dose of the comparator drug was adjusted to maintain the patient's Hb within a target range of 11 to 13 g/dL. Of the 480 patients in the comparator drug group, 170 received darbepoetin alfa, 134 received epoetin alfa, and 176 received epoetin beta.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Treatment Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="748"/>
                <participants group_id="P2" count="480"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="492"/>
                <participants group_id="P2" count="302"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="256"/>
                <participants group_id="P2" count="178"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="88"/>
                <participants group_id="P2" count="62"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Refused Treatment</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Renal Transplant</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Mircera Commercialization</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other Unrelated to Safety and Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Extended Treatment Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="453">39 patients who completed the first treatment period refused to enter the extended treatment period.</participants>
                <participants group_id="P2" count="250">52 patients who completed the first treatment period refused to enter the extended treatment period.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="94"/>
                <participants group_id="P2" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="359"/>
                <participants group_id="P2" count="191"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Refused Treatment</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Renal Transplant</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Mircera Commercialization</title>
              <participants_list>
                <participants group_id="P1" count="188"/>
                <participants group_id="P2" count="93"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other Unrelated to Safety and Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
                <participants group_id="P2" count="43"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Methoxy Polyethylene Glycol-Epoetin Beta</title>
          <description>Patients received the same weekly dose of methoxy polyethylene glycol-epoetin beta via the same route of administration (iv or sc) as they received in the Phase II or Phase III study that qualified the patient for participation in this study. Methoxy polyethylene glycol-epoetin beta was administered every 2 or every 4 weeks in the initial 104-week treatment period. Patients on a 4-week dosing interval were switched to once-monthly administration in the 24-month extension phase. The dose of methoxy polyethylene glycol-epoetin beta was adjusted to maintain the patient's hemoglobin (Hb) within a target range of 11 to 13 g/dL.</description>
        </group>
        <group group_id="B2">
          <title>Comparator ESA</title>
          <description>Patients received the same comparator ESA [epoetin alfa, epoetin beta, or darbepoetin alfa] at the same weekly dose and dosing interval via the same route of administration (iv or sc) as they received in the Phase III study that qualified the patient for participation in this study. The dose of the comparator drug was adjusted to maintain the patient's Hb within a target range of 11 to 13 g/dL. Of the 480 patients in the comparator drug group, 170 received darbepoetin alfa, 134 received epoetin alfa, and 176 received epoetin beta.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="748"/>
            <count group_id="B2" value="480"/>
            <count group_id="B3" value="1228"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.2" spread="14.80"/>
                    <measurement group_id="B2" value="61.9" spread="14.42"/>
                    <measurement group_id="B3" value="61.5" spread="14.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="327"/>
                    <measurement group_id="B2" value="223"/>
                    <measurement group_id="B3" value="550"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="421"/>
                    <measurement group_id="B2" value="257"/>
                    <measurement group_id="B3" value="678"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Hemoglobin Concentration to the Last Month of Study Participation</title>
        <description>Blood samples were collected at each study visit, that is, every 4 weeks for the first 12 weeks, every 12 weeks until week 105 of the first study period, every 3 months thereafter, and at the end of study or the last visit if the patient discontinued the study prematurely.</description>
        <time_frame>Baseline to the end of the study (Up to 49 Months)</time_frame>
        <population>Analysis includes participants from the Intent-to-treat population (all patients who received at least 1 dose of methoxy polyethylene glycol-epoetin beta or a comparator ESA) who had hemoglobin values available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Methoxy Polyethylene Glycol-Epoetin Beta</title>
            <description>Patients received the same weekly dose of methoxy polyethylene glycol-epoetin beta via the same route of administration (iv or sc) as they received in the Phase II or Phase III study that qualified the patient for participation in this study. Methoxy polyethylene glycol-epoetin beta was administered every 2 or every 4 weeks in the initial 104-week treatment period. Patients on a 4-week dosing interval were switched to once-monthly administration in the 24-month extension phase. The dose of methoxy polyethylene glycol-epoetin beta was adjusted to maintain the patient's hemoglobin (Hb) within a target range of 11 to 13 g/dL.</description>
          </group>
          <group group_id="O2">
            <title>Comparator ESA</title>
            <description>Patients received the same comparator ESA [epoetin alfa, epoetin beta, or darbepoetin alfa] at the same weekly dose and dosing interval via the same route of administration (iv or sc) as they received in the Phase III study that qualified the patient for participation in this study. The dose of the comparator drug was adjusted to maintain the patient's Hb within a target range of 11 to 13 g/dL. Of the 480 patients in the comparator drug group, 170 received darbepoetin alfa, 134 received epoetin alfa, and 176 received epoetin beta.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hemoglobin Concentration to the Last Month of Study Participation</title>
          <description>Blood samples were collected at each study visit, that is, every 4 weeks for the first 12 weeks, every 12 weeks until week 105 of the first study period, every 3 months thereafter, and at the end of study or the last visit if the patient discontinued the study prematurely.</description>
          <population>Analysis includes participants from the Intent-to-treat population (all patients who received at least 1 dose of methoxy polyethylene glycol-epoetin beta or a comparator ESA) who had hemoglobin values available for analysis.</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="735"/>
                <count group_id="O2" value="476"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.55" spread="1.832"/>
                    <measurement group_id="O2" value="-0.38" spread="1.614"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Who Had at Least 1 Adverse Event</title>
        <description>See the adverse events section of the results for more information.</description>
        <time_frame>From first dose of study drug to date of last contact or 30 days after last drug dose (Up to 49 months)</time_frame>
        <population>Intent-to-treat population: All patients who received at least 1 dose of methoxy polyethylene glycol-epoetin beta or a comparator ESA.</population>
        <group_list>
          <group group_id="O1">
            <title>Methoxy Polyethylene Glycol-Epoetin Beta</title>
            <description>Patients received the same weekly dose of methoxy polyethylene glycol-epoetin beta via the same route of administration (iv or sc) as they received in the Phase II or Phase III study that qualified the patient for participation in this study. Methoxy polyethylene glycol-epoetin beta was administered every 2 or every 4 weeks in the initial 104-week treatment period. Patients on a 4-week dosing interval were switched to once-monthly administration in the 24-month extension phase. The dose of methoxy polyethylene glycol-epoetin beta was adjusted to maintain the patient's hemoglobin (Hb) within a target range of 11 to 13 g/dL.</description>
          </group>
          <group group_id="O2">
            <title>Comparator ESA</title>
            <description>Patients received the same comparator ESA [epoetin alfa, epoetin beta, or darbepoetin alfa] at the same weekly dose and dosing interval via the same route of administration (iv or sc) as they received in the Phase III study that qualified the patient for participation in this study. The dose of the comparator drug was adjusted to maintain the patient's Hb within a target range of 11 to 13 g/dL. Of the 480 patients in the comparator drug group, 170 received darbepoetin alfa, 134 received epoetin alfa, and 176 received epoetin beta.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Who Had at Least 1 Adverse Event</title>
          <description>See the adverse events section of the results for more information.</description>
          <population>Intent-to-treat population: All patients who received at least 1 dose of methoxy polyethylene glycol-epoetin beta or a comparator ESA.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="748"/>
                <count group_id="O2" value="480"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.3"/>
                    <measurement group_id="O2" value="93.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first dose of study drug to date of last contact or 30 days after last drug dose (Up to 49 months)</time_frame>
      <desc>Intent-to-treat population: All patients who received at least 1 dose of methoxy polyethylene glycol-epoetin beta or a comparator ESA.</desc>
      <group_list>
        <group group_id="E1">
          <title>Methoxy Polyethylene Glycol-Epoetin Beta</title>
          <description>Patients received the same weekly dose of methoxy polyethylene glycol-epoetin beta via the same route of administration (iv or sc) as they received in the Phase II or Phase III study that qualified the patient for participation in this study. Methoxy polyethylene glycol-epoetin beta was administered every 2 or every 4 weeks in the initial 104-week treatment period. Patients on a 4-week dosing interval were switched to once-monthly administration in the 24-month extension phase. The dose of methoxy polyethylene glycol-epoetin beta was adjusted to maintain the patient's hemoglobin (Hb) within a target range of 11 to 13 g/dL.</description>
        </group>
        <group group_id="E2">
          <title>Comparator ESA</title>
          <description>Patients received the same comparator ESA [epoetin alfa, epoetin beta, or darbepoetin alfa] at the same weekly dose and dosing interval via the same route of administration (iv or sc) as they received in the Phase III study that qualified the patient for participation in this study. The dose of the comparator drug was adjusted to maintain the patient's Hb within a target range of 11 to 13 g/dL. Of the 480 patients in the comparator drug group, 170 received darbepoetin alfa, 134 received epoetin alfa, and 176 received epoetin beta.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (12.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="499" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="316" subjects_at_risk="480"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>COAGULOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>DISSEMINATED INTRAVASCULAR COAGULATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>HEPARIN-INDUCED THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>HYPOPROTHROMBINAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>LEUKOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE CONGESTIVE</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ACUTE MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>CARDIAC ARREST</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ANGINA PECTORIS</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ACUTE CORONARY SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>CARDIO-RESPIRATORY ARREST</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL ISCHAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ATRIAL FLUTTER</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>VENTRICULAR FIBRILLATION</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>BRADYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ARRHYTHMIA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>CARDIOGENIC SHOCK</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>CARDIOPULMONARY FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ANGINA UNSTABLE</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ATRIOVENTRICULAR BLOCK COMPLETE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>PERICARDITIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>VENTRICULAR TACHYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ARTERIOSCLEROSIS CORONARY ARTERY</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>LEFT VENTRICULAR FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>MITRAL VALVE INCOMPETENCE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>SUPRAVENTRICULAR TACHYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>TACHYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ATRIOVENTRICULAR BLOCK</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE CHRONIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>COR PULMONALE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY OCCLUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ISCHAEMIC CARDIOMYOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>PALPITATIONS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>SICK SINUS SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>AORTIC VALVE STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ATRIOVENTRICULAR BLOCK FIRST DEGREE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ATRIOVENTRICULAR DISSOCIATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>BUNDLE BRANCH BLOCK RIGHT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>CARDIOMYOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>CARDIOVASCULAR DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>CONGESTIVE CARDIOMYOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY DISSECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ELECTROMECHANICAL DISSOCIATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>HYPERTENSIVE CARDIOMYOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>HYPERTENSIVE HEART DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>HYPERTROPHIC CARDIOMYOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>LEFT VENTRICULAR HYPERTROPHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>NODAL ARRHYTHMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>PERICARDIAL DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>PERICARDIAL EFFUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>SINUS ARRHYTHMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>TACHYARRHYTHMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>VENTRICULAR ARRHYTHMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>VENTRICULAR EXTRASYSTOLES</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>VENTRICULAR HYPERTROPHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>GASTROINTESTINAL ANGIODYSPLASIA HAEMORRHAGIC</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>CONGENITAL CYSTIC KIDNEY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>VERTIGO</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>VERTIGO POSITIONAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERPARATHYROIDISM SECONDARY</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>HYPERPARATHYROIDISM TERTIARY</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>HYPERPARATHYROIDISM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>HYPERTHYROIDISM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>GOITRE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>CATARACT</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>CONJUNCTIVAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>GLAUCOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>RETINAL DETACHMENT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>PERITONITIS</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>GASTRITIS</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>PANCREATITIS</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>UPPER GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>DIVERTICULUM INTESTINAL HAEMORRHAGIC</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>GASTRIC ULCER HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>COLITIS ISCHAEMIC</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>SMALL INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>COLITIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>COLONIC POLYP</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>INTESTINAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>MELAENA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ABDOMINAL HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>DIVERTICULAR PERFORATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>DUODENAL ULCER HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>DUODENITIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>GASTROOESOPHAGEAL REFLUX DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>HAEMORRHOIDS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ILEUS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>INGUINAL HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>INTESTINAL ISCHAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>PANCREATITIS ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>RECTAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ABDOMINAL STRANGULATED HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>CAECITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>DIVERTICULUM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>DIVERTICULUM INTESTINAL</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>DUODENAL ULCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>GASTRITIS HAEMORRHAGIC</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>LARGE INTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>PANCREATITIS CHRONIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>REFLUX OESOPHAGITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>SUBILEUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ABDOMINAL HERNIA OBSTRUCTIVE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ACUTE ABDOMEN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ASCITES</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>DIVERTICULITIS INTESTINAL HAEMORRHAGIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>DUODENAL OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>DUODENAL ULCER PERFORATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>DUODENITIS HAEMORRHAGIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>DYSPHAGIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>EROSIVE DUODENITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>EROSIVE OESOPHAGITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>FLATULENCE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>GASTRIC DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>GASTRITIS EROSIVE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>GASTRODUODENITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL TELANGIECTASIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL ULCER HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>HAEMATEMESIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ILEUS PARALYTIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>INTESTINAL PERFORATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>IRRITABLE BOWEL SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>LOWER GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>MEGACOLON</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>PEPTIC ULCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>RETROPERITONEAL FIBROSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>RETROPERITONEAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>SMALL INTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>DEATH</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>NON-CARDIAC CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>CATHETER THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>SUDDEN DEATH</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>CATHETER RELATED COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>MULTI-ORGAN FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>GENERAL PHYSICAL HEALTH DETERIORATION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>HYPERPYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>HERNIA OBSTRUCTIVE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>HYPERTHERMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>SUDDEN CARDIAC DEATH</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>VESSEL PUNCTURE SITE HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>CALCINOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>CATHETER SITE HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>CHEST DISCOMFORT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>CHILLS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>IMPAIRED HEALING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>IMPLANT SITE NECROSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>INFLAMMATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>MULTI-ORGAN DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>OEDEMA DUE TO RENAL DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>PSEUDOCYST</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>CHOLELITHIASIS</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>BILE DUCT OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>BILE DUCT STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>BILE DUCT STONE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>GALLBLADDER POLYP</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>HEPATIC CIRRHOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>HEPATIC CONGESTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>HEPATIC FIBROSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>HEPATITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>HEPATOSPLENOMEGALY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>JAUNDICE CHOLESTATIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>KIDNEY TRANSPLANT REJECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ANAPHYLACTIC REACTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ANAPHYLACTOID REACTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>CONTRAST MEDIA ALLERGY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>DRUG HYPERSENSITIVITY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>CATHETER SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ARTERIOVENOUS GRAFT SITE INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>GANGRENE</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>SEPTIC SHOCK</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>BRONCHOPNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>CATHETER RELATED INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>CLOSTRIDIUM DIFFICILE COLITIS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL BACTERAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS VIRAL</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>OSTEOMYELITIS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>DIABETIC GANGRENE</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>DIVERTICULITIS</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>CENTRAL LINE INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>APPENDICITIS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ARTERIOVENOUS FISTULA SITE INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ENDOCARDITIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>LOWER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>POSTOPERATIVE WOUND INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>UROSEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>INFECTED SKIN ULCER</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>PERITONITIS BACTERIAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>WOUND INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>BACTERAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>CATHETER BACTERAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS INFECTIVE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>DIABETIC FOOT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>INTERVERTEBRAL DISCITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>LUNG INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ABDOMINAL WALL ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ABSCESS LIMB</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>BACTERIAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>BACTERIAL SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>CATHETER SITE INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>CELLULITIS GANGRENOUS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ERYSIPELAS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>FUNGAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>GRAFT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>GROIN ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>PNEUMONIA STAPHYLOCOCCAL</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>PNEUMONIA STREPTOCOCCAL</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>PYELONEPHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>STREPTOCOCCAL SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>VIRAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ABDOMINAL SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ANOGENITAL WARTS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ARTERIOSCLEROTIC GANGRENE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ARTERITIS INFECTIVE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ARTHRITIS BACTERIAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ARTHRITIS INFECTIVE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>BACTERIAL DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>BALANOPOSTHITIS INFECTIVE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>CELLULITIS OF MALE EXTERNAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>GENITAL ORGAN CELLULITIS STREPTOCOCCAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>CHRONIC TONSILLITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>CYSTITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>DISSEMINATED TUBERCULOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>EMPHYSEMATOUS CHOLECYSTITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>EMPYEMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ENDOCARDITIS STAPHYLOCOCCAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ENTEROCOCCAL SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ESCHERICHIA SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ESCHERICHIA URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>EYE INFECTION STAPHYLOCOCCAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>FUNGAL PERITONITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>GASTRIC ULCER HELICOBACTER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>HAEMATOMA INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>HEPATITIS C</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>INFECTED BITES</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>INFECTED CYST</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>INFECTIVE EXACERBATION OF CHRONIC OBSTRUCTIVE AIRWAYS DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>INFLUENZA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>KLEBSIELLA SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>LIVER ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>LOBAR PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>LOCALISED INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>NOSOCOMIAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ORAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>OSTEOMYELITIS CHRONIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>PANCREAS INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>PAROTID ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>PHARYNGEAL ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>PHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>PNEUMOCOCCAL SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>PNEUMONIA BACTERIAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>PNEUMONIA KLEBSIELLA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>PNEUMONIA PRIMARY ATYPICAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>PSEUDOMEMBRANOUS COLITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>PULMONARY SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>PULMONARY TUBERCULOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>RECTAL ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>RESPIRATORY TRACT INFECTION VIRAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>SEPTIC ARTHRITIS STAPHYLOCOCCAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>SERRATIA BACTERAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>SERRATIA INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL OSTEOMYELITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>SUBCUTANEOUS ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>TUBERCULOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>TUBERCULOUS PLEURISY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>WEST NILE VIRAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>ARTERIOVENOUS FISTULA THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ARTERIOVENOUS GRAFT THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ARTERIOVENOUS FISTULA SITE COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>FEMORAL NECK FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ARTERIOVENOUS FISTULA SITE HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>PROCEDURAL HYPOTENSION</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>VASCULAR GRAFT COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>FEMUR FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>SUBDURAL HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>HIP FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ARTERIOVENOUS FISTULA ANEURYSM</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>PELVIC FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ARTERIOVENOUS GRAFT SITE HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>TENDON RUPTURE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>GRAFT THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>HEAD INJURY</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>INCISIONAL HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>OVERDOSE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>RADIUS FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>VASCULAR PSEUDOANEURYSM</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>WRIST FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ANAEMIA POSTOPERATIVE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ANKLE FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>CONCUSSION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>FACIAL BONES FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>FIBULA FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>HUMERUS FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>IN-STENT CORONARY ARTERY RESTENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>JOINT INJURY</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>LOWER LIMB FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>MULTIPLE FRACTURES</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>PNEUMOTHORAX TRAUMATIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>PUBIC RAMI FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>RIB FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>THERAPEUTIC AGENT TOXICITY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>TIBIA FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ACETABULUM FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ALCOHOL POISONING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ARTERIOVENOUS FISTULA OCCLUSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ARTERIOVENOUS FISTULA SITE HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ARTERIOVENOUS GRAFT ANEURYSM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>CHEST INJURY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>CLAVICLE FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>CONTUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>DELAYED RECOVERY FROM ANAESTHESIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>DEVICE MALFUNCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>DIALYSIS DEVICE COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>DISLOCATION OF JOINT PROSTHESIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>FALL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>FOOT FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>FOREARM FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>FRACTURED COCCYX</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>HEPATIC HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>JOINT DISLOCATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>LUMBAR VERTEBRAL FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>MUSCLE RUPTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>PERIORBITAL HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>PERIRENAL HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL PULMONARY EMBOLISM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>POSTOPERATIVE FEVER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>POSTOPERATIVE WOUND COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>POSTPERICARDIOTOMY SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>PROCEDURAL COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>PROCEDURAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>PROCEDURAL VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>SKULL FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>SOFT TISSUE INJURY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>SPLENIC RUPTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>SUBDURAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>SYNOVIAL RUPTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ULNA FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>UPPER LIMB FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>UROSTOMY COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>VASCULAR GRAFT OCCLUSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>WOUND</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>BACTERIAL CULTURE POSITIVE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>FLUID OVERLOAD</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>HYPERKALAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>HYPOGLYCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>DIABETIC FOOT</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>CACHEXIA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>DIABETES MELLITUS INADEQUATE CONTROL</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>HYPOCALCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>HYPERGLYCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>GOUT</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>HYPERCALCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>CALCIPHYLAXIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>DIABETES MELLITUS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ELECTROLYTE IMBALANCE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>FAILURE TO THRIVE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>FLUID RETENTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>HYPERVOLAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>HYPONATRAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>HYPOVOLAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>SPINAL OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>INTERVERTEBRAL DISC DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>MUSCULAR WEAKNESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>CERVICAL SPINAL STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>COSTOCHONDRITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>DACTYLITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>FASCIITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>FLANK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>HAEMARTHROSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>INTERVERTEBRAL DISC PROTRUSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>MUSCLE HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>MYOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>OSTEITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>OSTEODYSTROPHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>OSTEOLYSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>OSTEONECROSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>OSTEOPOROSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>POLYMYALGIA RHEUMATICA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ROTATOR CUFF SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>SOFT TISSUE NECROSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>SPINAL COLUMN STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>SYNOVITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>COLON CANCER</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>PROSTATE CANCER</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>LUNG NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>BREAST CANCER</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>LUNG CANCER METASTATIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>LUNG NEOPLASM MALIGNANT</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>RENAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>BLADDER TRANSITIONAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>COLON CANCER METASTATIC</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>LUNG SQUAMOUS CELL CARCINOMA STAGE UNSPECIFIED</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>METASTATIC NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>PANCREATIC CARCINOMA METASTATIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>RENAL NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ADENOID CYSTIC CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>BASAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>BLADDER NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>BREAST CANCER IN SITU</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>BREAST CANCER METASTATIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>CHRONIC LYMPHOCYTIC LEUKAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>COLON ADENOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>LUNG ADENOCARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>MALIGNANT PLEURAL EFFUSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>METASTASES TO CENTRAL NERVOUS SYSTEM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>METASTASES TO LIVER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>METASTATIC GASTRIC CANCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>MULTIPLE MYELOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>PANCREATIC NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>PARATHYROID TUMOUR</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>PROSTATE CANCER METASTATIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>RENAL CANCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>RENAL ONCOCYTOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>SKIN CANCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>SMALL CELL LUNG CANCER METASTATIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>SMALL CELL LUNG CANCER STAGE UNSPECIFIED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>SQUAMOUS CELL CARCINOMA OF SKIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>THYROID CANCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>THYROID NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>URINARY TRACT NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>UTERINE LEIOMYOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CEREBROVASCULAR ACCIDENT</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>TRANSIENT ISCHAEMIC ATTACK</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>CEREBRAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ISCHAEMIC STROKE</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>CEREBRAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>CAROTID ARTERY STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>CARPAL TUNNEL SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>HAEMORRHAGIC STROKE</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>CEREBROVASCULAR DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>CONVULSION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>CEREBRAL ISCHAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ISCHAEMIC CEREBRAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>PRESYNCOPE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>EMBOLIC CEREBRAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>EMBOLIC STROKE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>EPILEPSY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>HAEMORRHAGE INTRACRANIAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>HYPOGLYCAEMIC COMA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>HYPOXIC ENCEPHALOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>LACUNAR INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>REVERSIBLE ISCHAEMIC NEUROLOGICAL DEFICIT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>URAEMIC NEUROPATHY</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ALTERED STATE OF CONSCIOUSNESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ANOXIC ENCEPHALOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>BALANCE DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>BENIGN INTRACRANIAL HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>CEREBRAL ARTERIOSCLEROSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>CEREBRAL ATROPHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>CERVICAL MYELOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>COGNITIVE DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>COMA HEPATIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>COMPLEX PARTIAL SEIZURES</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>DEMENTIA ALZHEIMER’S TYPE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>DEMENTIA WITH LEWY BODIES</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ENCEPHALOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>HAEMORRHAGIC CEREBRAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>HEPATIC ENCEPHALOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>HYDROCEPHALUS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>HYPERTENSIVE ENCEPHALOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>INTRACRANIAL HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>LOSS OF CONSCIOUSNESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>METABOLIC ENCEPHALOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>MUSCLE SPASTICITY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>NEURALGIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>NEUROTOXICITY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>PARKINSON’S DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>PERIPHERAL SENSORIMOTOR NEUROPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>POLYNEUROPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>SENILE DEMENTIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>SPONDYLITIC MYELOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>STUPOR</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>SUBARACHNOID HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>MENTAL STATUS CHANGES</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>CONFUSIONAL STATE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ACUTE PSYCHOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ANXIETY DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>BIPOLAR I DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>COMPLETED SUICIDE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>DELIRIUM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>DEPRESSION SUICIDAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>DISORIENTATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>MAJOR DEPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>MENTAL DISORDER DUE TO A GENERAL MEDICAL CONDITION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>PSYCHOTIC DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>SUICIDE ATTEMPT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>RENAL FAILURE CHRONIC</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>HAEMATURIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>AZOTAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>CALCULUS URETERIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>CYSTITIS HAEMORRHAGIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>NEPHROLITHIASIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>RENAL IMPAIRMENT</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>NEPHROPATHY TOXIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>OBSTRUCTIVE UROPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>PYELOCALIECTASIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>RENAL CYST RUPTURED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>RENAL DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>RENAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>RENAL HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>RENAL TUBULAR NECROSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>URINARY BLADDER POLYP</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>BENIGN PROSTATIC HYPERPLASIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>CERVIX INFLAMMATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>CYSTOCELE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>GENITAL PROLAPSE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>OVARIAN CYST</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>PROSTATISM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>PROSTATITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>TESTICULAR INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>UTERINE CERVICAL SQUAMOUS METAPLASIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>PULMONARY OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>PLEURAL EFFUSION</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>CHRONIC OBSTRUCTIVE PULMONARY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>PNEUMONIA ASPIRATION</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ACUTE PULMONARY OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>PULMONARY EMBOLISM</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ACUTE RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>NON-CARDIOGENIC PULMONARY OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>PULMONARY HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ASTHMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>EPISTAXIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>HAEMOTHORAX</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>BRONCHITIS CHRONIC</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>HYPOXIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>LUNG INFILTRATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ATELECTASIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>BRONCHOSPASM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>CHOKING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>EMPHYSEMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>HYDROTHORAX</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>MEDIASTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>PLEURITIC PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>PNEUMONITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>PULMONARY FIBROSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>PULMONARY GRANULOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>PULMONARY HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>PULMONARY VASCULITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>RESPIRATORY DISTRESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>TRACHEAL ULCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFLAMMATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>WEGENER’S GRANULOMATOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>SKIN ULCER</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ANGIOEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>DECUBITUS ULCER</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>DRY GANGRENE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>DERMATITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>DIABETIC NEUROPATHIC ULCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>DRUG ERUPTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>LIPODYSTROPHY ACQUIRED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>PENILE ULCERATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>SKIN DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>SKIN FISSURES</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HYPOTENSION</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>PERIPHERAL ISCHAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>DEEP VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>PERIPHERAL VASCULAR DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>DIABETIC VASCULAR DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>PERIPHERAL ARTERIAL OCCLUSIVE DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>HYPERTENSIVE CRISIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ARTERIAL THROMBOSIS LIMB</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>FEMORAL ARTERIAL STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>AORTIC ANEURYSM RUPTURE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ARTERIAL STENOSIS LIMB</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>HYPERTENSIVE EMERGENCY</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ORTHOSTATIC HYPOTENSION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>VENOUS STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ACCELERATED HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>AORTIC STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ARTERIAL STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ARTERIOSCLEROSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ARTERIOSCLEROSIS OBLITERANS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>CIRCULATORY COLLAPSE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>EXTREMITY NECROSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>FEMORAL ARTERY OCCLUSION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ILIAC ARTERY STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>INTERMITTENT CLAUDICATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>STEAL SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ANEURYSM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ANEURYSM RUPTURED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ANGIOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>AORTIC ANEURYSM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>AORTIC DISSECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ARTERIAL DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>BRACHIOCEPHALIC VEIN STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>FEMORAL ARTERY EMBOLISM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>HYPOVOLAEMIC SHOCK</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ISCHAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>JUGULAR VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>MICROANGIOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>PERIPHERAL ARTERY ANEURYSM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>PHLEBITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>SUBCLAVIAN VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>VASCULAR CALCIFICATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>VASCULAR RUPTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>VASCULAR STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>VASCULITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>VENA CAVA THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>VENOUS INSUFFICIENCY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>VENOUS THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="480"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (12.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="624" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="390" subjects_at_risk="480"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="480"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="480"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERPARATHYROIDISM SECONDARY</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="480"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="141" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="96" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="480"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="480"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="107" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="81" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>INFLUENZA</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="480"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>PROCEDURAL HYPOTENSION</sub_title>
                <counts group_id="E1" subjects_affected="97" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ARTERIOVENOUS FISTULA SITE COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="83" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ARTERIOVENOUS FISTULA THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ARTERIOVENOUS GRAFT THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>CONTUSION</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>VASCULAR GRAFT COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="480"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>FLUID OVERLOAD</sub_title>
                <counts group_id="E1" subjects_affected="83" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>HYPERKALAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>HYPERPHOSPHATAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="480"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>MUSCLE SPASMS</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="74" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" subjects_affected="76" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="480"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="83" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="480"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="480"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>RENAL FAILURE CHRONIC</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="480"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="79" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="480"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>PRURITUS</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="480"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="167" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="109" subjects_at_risk="480"/>
              </event>
              <event>
                <sub_title>HYPOTENSION</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="748"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="480"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Communications</name_or_title>
      <organization>Hoffmann-La Roche</organization>
      <phone>800-821-8590</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

